title: Longterm outcomes in patients with giant aneurysms secondary to Kawasaki disease.
abstract: OBJECTIVE
  Kawasaki disease (KD) has potentially serious cardiac complications including coronary artery aneurysms. Children who develop giant aneurysms (GA) are at increased risk of thrombosis and ischemia, and although longterm oral anticoagulation with warfarin is recommended, its efficacy has not been studied. We examined the longterm outcome of patients with GA secondary to KD, to determine if anticoagulation with warfarin aids in the prevention of myocardial ischemia.
  
  
  METHODS
  We studied patients with KD followed between May 1990 and April 2000.
  
  
  RESULTS
  Thirty-nine GA occurred in 2.2% of patients with KD (22/997 patients), and 33 non-GA were also identified in these patients. Patients were divided into 2 groups, those taking warfarin and no warfarin. Most patients in both groups were also taking antiplatelet agents. The demographics of the 2 groups were statistically similar, except the median duration of followup was significantly longer for patients in the no-warfarin group (6.9 vs 13.3 yrs; p = 0.008). Four early ischemic events (< 1 year after KD diagnosis) occurred (3 myocardial infarctions and one stroke). Screening for late ischemic events by stress nuclear medicine myocardial perfusion imaging revealed only one patient, in the no-warfarin group, with reversible perfusion defects. No patient had clinical signs or symptoms of late myocardial ischemia. Echocardiographic regression of aneurysms was observed in both groups. In the warfarin vs no-warfarin group, the diameters of the GA regressed a median 22% vs 32% (p = 0.27), and non-GA regressed a median of 30% vs 25% (p = 0.61). Compliance with anticoagulation was good, and no major bleeding complication of anticoagulation occurred.
  
  
  CONCLUSIONS
  Regression of GA occurred in most of our patients, and minimal late ischemia was observed. Further studies are required to evaluate the use of oral anticoagulation in patients with GA secondary to KD.
authors.affiliation: Departments of Pediatrics, Division of Rheumatology, Hospital for Sick Children Research Institute, University of Toronto, Toronto, Ontario, Canada.
authors.forename: Deborah M
authors.initials: DM
authors.lastname: Levy
authors.forename: Earl D
authors.initials: ED
authors.lastname: Silverman
authors.forename: M Patricia
authors.initials: MP
authors.lastname: Massicotte
authors.forename: Brian W
authors.initials: BW
authors.lastname: McCrindle
authors.forename: Rae S M
authors.initials: RS
authors.lastname: Yeung
mesh_terms: D000293:Adolescent; D000783:Aneurysm / Q000188:drug therapy* / Q000209:etiology* / Q000473:pathology; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D003328:Coronary Thrombosis / Q000517:prevention & control; D003331:Coronary Vessels / Q000473:pathology; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D009080:Mucocutaneous Lymph Node Syndrome / Q000150:complications*; D017202:Myocardial Ischemia / Q000517:prevention & control; D012189:Retrospective Studies; D016896:Treatment Outcome; D014859:Warfarin / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000925:Anticoagulants; D014859:Warfarin